title: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains.
abstract: Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease.
authors.affiliation: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA. leung.nelson@mayo.edu
authors.forename: N
authors.initials: N
authors.lastname: Leung
authors.forename: M A
authors.initials: MA
authors.lastname: Gertz
authors.forename: S R
authors.initials: SR
authors.lastname: Zeldenrust
authors.forename: S V
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: A
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: F C
authors.initials: FC
authors.lastname: Fervenza
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: M Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: J A
authors.initials: JA
authors.lastname: Lust
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: S R
authors.initials: SR
authors.lastname: Hayman
authors.forename: S J
authors.initials: SJ
authors.lastname: Russell
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
authors.forename: J L
authors.initials: JL
authors.lastname: Winters
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000652:urine; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood*; D007680:Kidney Neoplasms / Q000150:complications* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000473:pathology; D010951:Plasma Exchange; D051437:Renal Insufficiency / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007147:Immunoglobulin Light Chains